Pamplona Therapeutics

Pamplona Therapeutics, founded in 2022, is an innovative pharmaceutical company focused on AI-driven Targeted Protein Degradation (TPD) drug discovery. The company’s first candidate molecule has received FDA IND clinical trial approval.The company independently developed the ASTRIDE® algorithm platform, which is centered on AI technology and based on protein structure, to accelerate the design and development of new drugs. Concentrating on potential targets in the fields of oncology, autoimmune diseases, and chronic illnesses, Pamplona Therapeutics leverages targeted protein degradation technology, driven by science and data, to develop First-in-class and Best-in-class innovative drugs based on novel targets and mechanisms.